Cleveland BioLabs launches cancer drug developer; NexMed shares spike on late-stage cancer strategy;

 @FierceBiotech: Charles River Labs buys China's WuXi for $1.6B. Report | Follow @FierceBiotech 

 @JohnCFierce: The problem I see for Dendreon is that at this point an address clarification by the FDA could throw everyone in a tizzy. | Follow @JohnCFierce

> Cleveland BioLabs has launched a joint venture with a Russian venture capital group that will develop new cancer drugs. The launch triggered a $5.7 million investment into the new venture. Report

> NexMed says that FDA regulators have indicated that the developer could move into a late-stage trial for its primary liver cancer therapy, triggering a leap in its share value. Story

> Adventrx plans to resubmit its NDA for ANX-530, or Exelbine, in the fourth quarter of 2010. Release

> The start-up Blue Ash Pharmaceuticals, which is advancing an anti-arrhythmic drug developed first at P&G, is getting $2 million in fresh financing. Report

> After achieving its long-awaited FDA approval of the new sleep drug Silenor, Somaxon is preparing to market the drug in a specialty niche as it continues efforts to find a partner who can do the "heavy lifting."  Report

> The pharma company Therabel has taken an undisclosed equity stake in France's BioAlliance Pharma. Story

And Finally... Scientists have combined chemistry and biology research techniques to explain how certain bacteria grow structures on their surfaces that allow them to simultaneously cause illness and protect themselves from the body's defenses. Release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.